A Phase I Safety and Immunogenicity Trial of MVA-BN-HER2 Vaccine in Locally Advanced and Advanced HER2+ Breast Cancer (GENE TRANSFER PROTOCOL).
Phase of Trial: Phase I
Latest Information Update: 11 Mar 2011
At a glance
- Drugs MVA BN HER2 (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions
- Sponsors BN ImmunoTherapeutics
- 10 Dec 2010 Status changed from not yet recruiting to discontinued as reported by ClinicalTrials.gov.
- 20 Jul 2010 New trial record